Maganin ciwon sukari na iya inganta alamun cutar Parkinson
Lixisenatide, glucagon-kamar peptide-1 agonist mai karɓa (GLP-1RA) don maganin ciwon sukari, yana rage jinkirin dyskinesia a cikin marasa lafiya da farkon cutar Parkinson, bisa ga sakamakon gwajin gwaji na lokaci na 2 da aka buga a cikin New England Journal of Medicine. NEJM) a ranar 4 ga Afrilu, 2024.
Binciken, wanda Asibitin Jami'ar Toulouse (Faransa) ya jagoranta, ya ɗauki batutuwa 156, daidai da rarraba tsakanin ƙungiyar kula da lixisenatide da ƙungiyar placebo.Masu binciken sun auna tasirin miyagun ƙwayoyi ta amfani da rikicewar motsi (MDS-Rigrs) Part, tare da manyan maki na III, tare da maki mafi girma akan sikelin motsi da ke nuna rikice-rikice.Sakamakon ya nuna cewa a watan 12, makin MDS-UPDRS na III ya ragu da maki 0.04 (yana nuna ƙaramin ci gaba) a cikin rukunin lixisenatide kuma ya karu da maki 3.04 (yana nuna cutar da cutar) a cikin rukunin placebo.
Wani editan NEJM na zamani ya lura cewa, a saman, waɗannan bayanan sun nuna cewa lixisenatide gaba ɗaya ya hana ci gaban alamun cutar Parkinson a cikin watanni 12, amma wannan na iya zama kyakkyawan fata.Duk ma'auni na MDS-UPDRS, gami da Sashe na III, ma'auni ne masu haɗaka da suka ƙunshi sassa da yawa, kuma haɓakawa a wani ɓangaren na iya hana lalacewa a wani.Bugu da ƙari, ƙungiyoyin gwaji guda biyu na iya amfana kawai ta hanyar shiga cikin gwaji na asibiti.Duk da haka, bambance-bambancen da ke tsakanin ƙungiyoyin gwaji guda biyu sun zama ainihin gaske, kuma sakamakon ya goyi bayan tasirin lixisenatide akan alamun cutar Parkinson da yiwuwar cututtuka.
Dangane da tsaro, kashi 46 cikin 100 na mutanen da aka yi musu magani da lixisenatide sun fuskanci tashin zuciya sannan kashi 13 cikin 100 sun fuskanci amai. Editan NEJM ya nuna cewa abubuwan da ke haifar da lahani na iya hana yaduwar amfani da lixisenatide wajen magance cutar Parkinson, don haka ci gaba da bincike. rage yawan kashi da sauran hanyoyin taimako zai zama mahimmanci.
"A cikin wannan gwaji, bambancin maki na MDS-UPDRS yana da mahimmanci a kididdiga amma kadan bayan watanni 12 na jiyya tare da lixisenatide. Muhimmancin wannan binciken bai dogara da girman canjin ba, amma a cikin abin da yake nunawa."Editan da aka ambata a baya ya rubuta, "Babban damuwa ga mafi yawan marasa lafiya na Parkinson ba shine halin da suke ciki ba, amma tsoron ci gaba da cututtuka. Idan lixisenatide ya inganta maki MDS-UPDRS da mafi yawan maki 3, to, ƙimar magani na miyagun ƙwayoyi na iya iyakancewa ((. musamman idan aka yi la'akari da illarsa, idan ingancin lixisenatide ya haɗu, yana ƙaruwa da maki 3 a kowace shekara a cikin shekaru 5 zuwa 10 ko fiye, to wannan na iya zama ingantaccen magani mataki na gaba tabbas shine don gudanar da gwaji na tsawon lokaci."
Kamfanin samar da magunguna na Faransa Sanofi (SNY.US), Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da lixisenatide don kula da nau'in ciwon sukari na 2 a cikin 2016, wanda ya zama GLP-1RA na 5 da ake tallatawa a duniya. daga gwaje-gwajen asibiti, ba shi da tasiri wajen rage glucose kamar takwarorinsa na liraglutide da Exendin-4, kuma shigowar sa cikin kasuwar Amurka ya zo daga baya fiye da nasu, wanda hakan yana da wahala samfurin ya sami gindin zama.A cikin 2023, an cire lixisenatide daga kasuwar Amurka.Sanofi ya yi bayanin cewa hakan ya faru ne saboda dalilai na kasuwanci maimakon aminci ko matsalolin ingancin maganin.
Cutar Parkinson cuta ce ta neurodegenerative wacce ke faruwa galibi a cikin masu matsakaici da kuma manya, galibi ana nuna ta da rawar jiki, dagewa da raguwar motsi, tare da wani dalili da ba a tantance ba.A halin yanzu, jigon jiyya don cutar Parkinson shine maganin maye gurbin dopaminergic, wanda da farko yana aiki don inganta bayyanar cututtuka kuma ba shi da tabbataccen shaida na shafar ci gaban cuta.
Yawancin binciken da suka gabata sun gano cewa masu karɓar masu karɓar GLP-1 suna rage kumburin kwakwalwa.Neuroinflammation yana haifar da asarar ci gaba na ƙwayoyin kwakwalwa masu samar da dopamine, ainihin yanayin cututtukan cututtukan Parkinson.Duk da haka, kawai GLP-1 agonists masu karɓa waɗanda ke da damar yin amfani da kwakwalwa suna da tasiri a cikin cutar Parkinson, kuma kwanan nan semaglutide da liraglutide, waɗanda aka sani da tasirin asarar nauyi, ba su nuna yiwuwar yin maganin cutar Parkinson ba.
A baya can, wani gwaji da ƙungiyar masu bincike a Cibiyar Nazarin Neurology ta Jami'ar London (UK) ta gudanar ya gano cewa exenatide, wanda ke da tsari mai kama da lixisenatide, ya inganta alamun cutar Parkinson.Sakamakon gwajin ya nuna cewa a cikin makonni 60, marasa lafiya da aka yi amfani da su tare da exenatide sun sami raguwar maki 1 a cikin maki MDS-UPDRS, yayin da waɗanda aka bi da su tare da placebo sun sami ci gaba na 2.1-point.Haɗin gwiwar Eli Lilly (LLY.US), babban kamfanin harhada magunguna na Amurka, exenatide shine farkon GLP-1 agonist mai karɓa na duniya, wanda ya mamaye kasuwa tsawon shekaru biyar.
Bisa kididdigar da aka yi, akalla shida GLP-1 agonists an gwada ko ana gwada su don tasirin su wajen magance cutar Parkinson.
A cewar kungiyar masu fama da cutar Parkinson, a halin yanzu akwai masu cutar Parkinson miliyan 5.7 a duk duniya, inda kusan miliyan 2.7 ke zaune a kasar Sin.Nan da shekarar 2030, kasar Sin za ta samu rabin yawan jama'ar cutar Parkinson a duniya.Kasuwar magungunan cutar Parkinson ta duniya za ta sami siyar da RMB biliyan 38.2 a cikin 2023 kuma ana sa ran ya kai RMB biliyan 61.24 a cikin 2030, a cewar DIResaerch (DIResaerch).
Lokacin aikawa: Afrilu-24-2024
.png)
